Coté, D., Eustace, A., Toomey, S., Cremona, M., Milewska, M., Furney, S., . . . Madden, S. (2018). Germline single nucleotide polymorphisms in ERBB3 and BARD1 genes result in a worse relapse free survival response for HER2-positive breast cancer patients treated with adjuvant based docetaxel, carboplatin and trastuzumab (TCH). PLoS One.
Citação norma ChicagoCoté, Damien, et al. "Germline Single Nucleotide Polymorphisms in ERBB3 and BARD1 Genes Result in a Worse Relapse Free Survival Response for HER2-positive Breast Cancer Patients Treated With Adjuvant Based Docetaxel, Carboplatin and Trastuzumab (TCH)." PLoS One 2018.
Citação norma MLACoté, Damien, et al. "Germline Single Nucleotide Polymorphisms in ERBB3 and BARD1 Genes Result in a Worse Relapse Free Survival Response for HER2-positive Breast Cancer Patients Treated With Adjuvant Based Docetaxel, Carboplatin and Trastuzumab (TCH)." PLoS One 2018.